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Abstract
The exact prediction of outcome of patients with Merkel cell carcinoma (MCC) of the skin is difficult to determine, although
several attempts have been made to identify clinico-pathologic prognostic factors. The Ki67 proliferative index is a well-known
marker routinely used to define the prognosis of patients with neuroendocrine neoplasms. However, its prognostic value has been
poorly investigated in MCC, and available published results are often contradictory mainly because restricted to small series in
the absence of standardized methods for Ki67 evaluation. For this reason, we explored the potential prognostic role of Ki67
proliferative index in a large series of MCCs using the WHO standardized method of counting positive cells in at least 500 tumor
cells in hot spot areas on camera-captured printed images. In addition, since MCC may be considered as the cutaneous counter-
part of digestive neuroendocrine carcinomas (NECs), we decided to stratify MCCs using the available and efficient Ki67
threshold of 55%, which was found prognostic in digestive NECs. This choice was also supported by the Youden index analysis.
In addition, we analyzed the prognostic value of other clinico-pathologic parameters using both univariate and multivariate
analysis. Ki67 index appeared significantly associated with prognosis at univariate analysis together with stage IV, lack of
MCPyV, and p63 expression, but not at the multivariate analysis, where survival resulted independently influenced by p63
expression and tumor stage, only.
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Introduction
Merkel cell carcinoma (MCC) is a rare neuroendocrine carci-
noma of the skin, but its incidence has largely increased over
the last 20 years, probably depending on the increasing effects
of risk factors such as advanced age, UV exposure, and system-
ic immunosuppression [1]. The reported annual incidence
varies between 0.1 and 0.88 per 100,000 people, with differ-
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ences among geographical regions: higher rates have been ob-
served in Australia and New Zealand and the lowest in Eastern
France and Scotland [2]. MCC is more frequently observed in
elderly white male patients (mean age at diagnosis of
73.6 years), although younger patients, mostly if immunosup-
pressed due to organ transplantation, can also be affected.MCC
incidence is also increased in patients with other malignancies
including melanoma, multiple myeloma, and non-Hodgkin
lymphoma, especially chronic lymphocytic leukemia [2].
MCC is an aggressive cancer, and several attempts have
been made to identify clinico-pathologic factors useful to strat-
ify patients in different prognostic categories. From an etiolog-
ical point of view, MCC can be divided into two main groups
with apparent different behaviors on the basis of the presence or
absence of an associated infection byMerkel cell polyomavirus
(MCPyV). MCC unassociated with MCPyV infection seems to
show a worse prognosis [3]. However, although several prog-
nostic markers have been proposed, the exact prediction of the
individual outcome remains difficult to be determined.
Ki67 proliferative index is a well-known prognostic marker
for both well-differentiated neuroendocrine tumors (NETs)
and poorly differentiated neuroendocrine carcinomas (NECs)
of the digestive system, and is currently routinely evaluated in
their diagnostic work-up [4]. Although its prognostic value
has also been recognized in other neuroendocrine neoplasms
(NENs), such as those located in the pituitary, parathyroid,
and lung [5–8], Ki67 proliferative index has been poorly in-
vestigated in cutaneous MCC; thus, its role remains to be
clarified.
In the present retrospective study, we explored the prog-
nostic role of Ki67 proliferative index in a large series of
MCCs integrating our results with literature findings. In addi-
tion, we investigated other potential clinico-pathologic prog-
nosticators, with the aim to identify useful parameters to strat-
ify MCC patients in different risk categories.
Materials and Methods
Cases
The surgical pathology databases of the Units of Pathology of
the ASST Sette Laghi/University of Insubria (Varese, Italy),
of the Bellaria Hospital/University of Bologna (Bologna,
Italy), of the Istituto Ortopedico Rizzoli (Bologna, Italy),
and of Città della Salute e della Scienza/University of Turin
(Turin, Italy) were retrospectively analyzed to identify cuta-
neous MCCs diagnosed between 1993 and 2015.
The clinico-pathological information including gender, age
at the time of diagnosis, tumor site and size, presence of lymph
node and/or distant metastases, stage, and available clinical
follow-up data were collected from hospital medical records,
from general physician or referring specialist, and from local
Tumor Registry. Patients were followed up for at least
36 months after surgery.
Morphological and Immunohistochemical Analysis
Tissues were fixed in buffered formalin and routinely proc-
essed to paraffin. Histological slides were stained with hema-
toxylin and eosin and reviewed by three pathologists with an
expertise in neuroendocrine neoplasms (SA, SLR, and SU) to
confirm the diagnosis and to evaluate the following morpho-
logical parameters: diameter, thickness of infiltration, mitotic
count (number of mitoses per 2 mm2), angioinvasion, and
margin status. In general, immunohistochemical stains for
synaptophysin, chromogranin A, and cytokeratin 20 were al-
ready available because routinely performed in the diagnostic
workup. The other immunohistochemical markers, including
Ki67, p63, and MCPyV, were performed when missing in the
original records. Immunohistochemistry was performed in an
automated stainer (Benchmark XT; Ventana Medical
Systems, Tucson, AZ) using 3-μm-thick sections and the an-
tibodies listed in Table 1. Ki67 proliferative index was evalu-
ated in one selected block and always at distance from ulcer-
ation, if present. The distribution of Ki67 labelling was rather
homogeneous in cases with the highest scores (> 55%), while
it was heterogeneous when the percentage of positive cells
was lower. In agreement with the most recent guidelines,
Ki67 proliferative index in case with heterogeneous Ki67 ex-
pression was evaluated in the hot spot area (selected at low
magnification) by counting the number of positive cells in at
least 500 tumor cells (range 500–2000 neoplastic cells) on
camera-captured printed images [4, 9].
Statistical and Survival Analysis
Summary statistics have been reported as number and percent-
age, mean (± standard deviation-SD) or median (standard er-
ror (SE), and corresponding 95% confidence intervals (CI))
when appropriate. Student’s t test has been performed to com-
pare continuous variable across groups. Chi square tests were
used to compare percentage thresholds across groups. All pos-
sible prognostic factors were submitted to a Cox proportional-
hazard regression. All factors with a p level ≤ 0.05 then en-
tered in a multivariate Cox regression, along with potential
confounders. Hazard ratios (HR) and 95% CI are also indicat-
ed. Kaplan–Meier estimator was used to estimate the survival
function from lifetime data including overall survival and
disease-specific survival cumulative rates. Formal test for
equality of survivor function was performed by log rank test.
Optimal cut-point for Ki67 index was investigated using
Youden’s index for the receiver operating characteristic
(ROC) curve analysis. A p value < 0.05 was considered sig-
nificant. All tests were two-sided. Analyses were performed
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with Stata14.2 (®2013 Stata Corp Austin, US) and SPSS 26.0
(®2019 SPSS Inc., Chicago, IL, USA).
Revision of the Literature
The PubMed database of the National Center for
Biotechnology Information (NCBI) of the US National
Library of Medicine was searched using the following string:
Ki67 [AND] Merkel cell carcinoma or proliferation [AND]
Merkel cell carcinoma. All articles written in English were
included. In addition, we revised the reference lists of each
paper selected in the PubMed database, with the aim of reduc-
ing the risk of missing pertinent articles. For each identified
article, the following information was considered: number of
cases in each series, the mean Ki67 proliferative index value,
the Ki67 cut-off selected for survival analyses, and correlation
of the Ki67 proliferative index with disease recurrence, overall
(OS), and disease-specific (DSS) survival.
Results
Clinico-Pathological and Immunohistochemical
Results
From a larger series of 100 patients, 84 cases had complete
clinical information and material for immunohistochemical
characterization available. The main clinico-pathologic fea-
tures of the 84 patients are summarized in Table 2. Males were
more frequently affected than females (p: 0.02), and the aver-
age age at diagnosis was 76 years (range 42–94 years). Mean
age was slightly higher among women (79 vs 74 years).
The mean diameter of MCCs was 2.49 cm (range 0.3–12),
and the mean thickness of infiltration was 9.24 mm (range
0.5–21 mm). All tumors showed the classical morphological
features of skin MCC including small to intermediate cells
with monomorphic nuclei displaying a finely dispersed chro-
matin, inconspicuous nucleoli, and scant cytoplasm. Co-
existent non-neuroendocrine components (including squa-
mous cell carcinoma or basal cell carcinoma) were never ob-
served. The mean mitotic count was 37 mitoses × 2mm2 and
54 cases (64%) showed angioinvasion. MCPyV nuclear im-
munoreactivity was identified in 71 cases (85%) and p63 ex-
pression in 38 cases (45%). ThemeanKi67 proliferative index
was 51.3%, ranging between 20 and 95%.
Table 2 Main clinico-pathological features of Merkel cell carcinomas
Gender
Men 50/84 (60%)
Women 34/84 (40%)
Age (years)
Mean 76
Range 42–94
Site
Head and neck 31
Trunk and buttock 17
Extremities (3) 36
Tumor diameter (cm)
Mean 2.49
Range 0.3–12
Tumor thickness (mm)
Mean 9.24
Range 0.5–21
Angioinvasion
Yes 54/84 (64%)
No 30/84 (36%)
Mitoses × 2mm2
Mean 37
Range 4–180
Ki67 ≥ 55% 30/84 (36%)
Ki67 < 55% 54/84 (64%)
Stage I 27/84 (32%)
II 23/84 (27%)
III 23/84 (27%)
IV 11 /84 (13%)
p63 + 38/84 (45%)
p63 − 46/84 (55%)
MCPyV + 71/84 (85%)
MCPyV − 13/84 (15%)
MCPyVMerkel cell polyomavirus
Table 1 Antibodies and antisera used
Antibody Dilution P/M (clone) Source
Synaptophysin 1:100 M (snp88) BioGenex Laboratories, San Ramon, CA, USA
Chromogranin A 1:1 M (LK2H10) Ventana Medical System, Tucson, AZ, USA
CK20 1:100 M (K520.8) Dako Corporation, Carpinteria, CA, USA
p63 1:2 M (4A4) Cell Marque, Roklin, CA, USA
Ki67 1:100 M (MIB1) Dako
MCPyV 1:100 M (CM2B4) Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA
P/M, polyclonal/monoclonal; CK, cytokeratin; MCPyV, Merkel cell polyomavirus
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Survival Analysis
The 5-year OS and DSS were 52% and 66%, respectively
(Fig. 1). The median OS and DSS for the whole series were
of 62 months (SE 9.376, 95% CI 43.622–80.378) and
96 months (SE 21.371, 95% CI 54.112–137.888), respective-
ly. Twenty-eight subjects (33% of the whole population) died
of their disease (DOD).
In the whole group, the univariate analysis showed that
AJCC stage (HR 1.864, 95% CI 1.295–2.682, p = 0.001),
p63 immunohistochemical expression (HR 8.304, 95% CI 3.
2 8 5–20 . 9 9 1 , p < 0 . 0 0 1 ) , a b s e n c e o f MCPyV
immunoreactivity (HR 2.740, 95% CI 1.133–6.628, p = 0.
025), and Ki67 index (HR 1.033, 95% CI 1.013–1.055, p =
0.002) were significantly associated with shorter DSS
(Table 3). Early AJCC stages of disease (I and II) presented
similar DSS rates. The most remarkable difference in survival
analysis was observed grouping stages I and II together
against grouped stages III and IV (log-rank test p < 0.001)
(Fig. 2). Fifty-four percent of patients with MCPyV-negative
MCCs died of disease versus 30% of patients with MCPyV-
positive MCCs (p = 0.019). Seventy-six percent of patients
with p63-positive MCCs died of disease, versus 24% of pa-
tients with p63-negative MCCs (p < 0.001) (Fig. 3).
Since Ki67 proliferative index > 55% has been demonstrat-
ed to be associated with worse prognosis in large series of
digestive NECs [10, 11], we performed the Kaplan-Meyer
estimator analysis using the same cut-off. Youden’s index
for ROC curve analysis identified 50.5% and 57.5% Ki67
values as optimal cut-points to detect DOD patients (J =
0.214), corroborating the use of the threshold of 55%.
Interestingly, when patients were classified according to out-
come (alive and well, alive with disease, died of other cause,
and died of disease), MCCs with Ki67 index > 55% were
more frequently observed in patients with progressive/
persistent disease (died of disease or alive with disease) than
in patients free of disease (p = 0.001) (Fig. 4).
These four factors (stage, p63, MCPyV, Ki67) were
entered into a multivariate analysis with patients’ age
and gender considered as correction factors. p63 expres-
sion (HR 7.254, 95% CI 2.792–18.843, p < 0.001) and
AJCC advanced stage (HR 1.934, 95% CI 1.239–3.018,
p = 0.004) remained the only independent factors signifi-
cantly affecting the DSS.
The prognostic role of the Ki67 proliferative index was also
explored in the subgroup of MCPyV-positive tumors (71
cases). Similar to what observed in the analysis of the entire
cohort, Ki67 proliferative index > 55% was statistically asso-
ciated with DSS at the univariate Cox proportional-hazard
regression analysis (p = 0.002, HR 1.041, 95% CI 1.0.15–
1.067), but it was not an independent prognostic factor at the
multivariate analysis as compared to p63 and AJCC advanced
stage.
Table 3 Cox univariate analysis of variables in relations to the disease-
specific survival
Variable HR (CI 95%) p value
Age (log) 1.016 (0.978–1.055) 0.42
Sex (male) 2.05 (0.871–4.826) 0.1
Size (cm) 0.94 (0.75–1.178) 0.592
Site (head and neck) 1.766 (0.821–3.798) 0.145
AJCC stage (log) 1.864 (1.295–2.682) 0.001
Margin status (R1) 0.736 (0.296–1.833) 0.51
Tumor thickness (log) 1.015 (0.946–1.089) 0.676
Tumor growth (infiltrative) 1.371 (0.637–2.955) 0.42
Angioinvasion (present) 2.177 (0.921–5.145) 0.076
Mitosis × HPF (log) 0.996 (0.986–1.006) 0.466
p63 (expressed) 8.304 (3.285–20.991) < 0.001
MCPyV (negative) 2.740 (1.133–6.628) 0.025
Ki67 index (log) 1.033 (1.013–1.055) 0.002
HR, hazard ratio; MCPyV, Merkel cell polyomavirus; HPF, high power
field
Fig. 1 Overall (a) and disease-
specific (b) survival of patients
with cutaneous Merkel cell
carcinoma
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Discussion
MCC of the skin is a rare neuroendocrine carcinoma with a
reported 5-year overall survival (OS) ranging from 30 to 60%
[12–14], and our findings are in line with this, showing a 5-
year OS of 52%, worse than the 5-year DSS (66%). This
probably reflects the characteristics of our cohort, where most
of patients were elderly (mean age 76 years) with other co-
morbidities and fatal events for unrelated causes. A similar
feature was observed by Jemec et al., whose series of MCCs
showed an OS worse than DSS after a mean follow-up time of
68.2 months [15]. Several different clinico-pathological fac-
tors negatively influencing patients’ survival have been pro-
posed for cutaneous MCC and included age, male gender,
clinical evidence of lymph node metastasis, depth of tumor
invasion, infiltrative growth pattern, loss of RB function, lack
of MCPyV immunoreactivity, and p63 expression [16–19].
More recently, promoter methylation of the immune
Fig. 3 Patients with Merkel cell carcinomas expressing MCPyV show a
better survival than patients with MCPyV-negative carcinomas (a).
MCPyV immunoreactivity is nuclear (b). Image (c) is an example of a
MCPyV-negative Merkel cell carcinoma. Expression of p63 by
neoplastic cells is associated with a worse prognosis (d). In image (e),
there is an example of p63-negative Merkel cell carcinoma. Note the
internal control in the basal layer of the normal epidermis. p63 is
expressed in the nuclei of cancerous cells (f)
Fig. 2 Disease-specific survival (DSS) related to AJCC tumor stage. Stages I and II presented similar DSS rates as compared to stages III and IV (a).
Different DSS was observed when grouping stage I with II and compared with stage III with stage IV grouped together (b) (log-rank test p < 0.001)
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checkpoint receptor CD279 (PD-1) and intratumor lympho-
cyte subtypes have been suggested as additional prognostic
factors [20, 21].
Ki67 proliferative index represents one of the most
important biological markers routinely used as prognosti-
cators in NENs. Its role was first demonstrated in pancre-
atic NETs [22, 23] and then in other digestive NETs [4] as
well as in NETs of other sites (e.g., in the pituitary gland)
[5, 6]. Recent data also suggest a prognostic role of Ki67
proliferative index in lung NENs and in non-epithelial
NENs, like olfactory neuroblastoma [8, 24]. In addition
to NETs, Ki67 proliferative index also plays a prognostic
role in NECs, as observed in the digestive system; indeed,
NECs with a Ki67 index > 55% show worse prognosis
than NECs with Ki67 index < 55%, despite a better initial
response of the former to chemotherapy [10, 11]. For all
these reasons, the evaluation of Ki67 is a required (diges-
tive system) or strongly recommended (other sites) param-
eter in the diagnostic work-up of NENs.
Despite the large available literature on the prognostic
role of Ki67 index in NENs, the available data on MCC
are heterogeneous, mainly due to the different methods
used to assess Ki67 proliferative index and the relatively
small number of cases studied in each series. Although
some studies suggested an association between Ki67
index and a more aggressive clinical behavior [19, 25,
26], others did not confirm this data [15, 27–32]
(Table 4). Although Ki67 is a continuous variable, the
current stratification of patients is generally related to
specific Ki67 cut-offs, which are able to separate patients
in different prognostic categories. However, standardized
method of evaluation such as that proposed by the WHO
[4, 9] is mandatory. Since MCC may be considered as the
cutaneous counterpart of visceral NECs and since no spe-
cific prognostic Ki67 cut-off has been identified for MCC,
we decided to use the only available and efficient Ki67
threshold (55%), although it refers to digestive NECs [10,
11]. This choice was also supported by the Youden index
analysis, which identified best cut-point Ki67 values at
52.5% and 57.5%. We observed an association between
Ki67 proliferative index higher than 55% and tumor re-
currence, in line with other published findings [27, 29, 35,
36, 39]. In addition, we demonstrated, at univariate anal-
ysis, the relationship between high Ki67 proliferative in-
dex and DSS, a finding not confirmed by previous studies
(Table 4). Indeed, in three studies, only the association
between Ki67 proliferative index and OS, but not DSS,
was observed [19, 25, 26]. These discrepancies may be
due to the different methods used to evaluate the Ki67
proliferative index and to the different cut-offs established
Fig. 4 Kaplan-Meyer curve (a) demonstrating that patients with Merkel
cell carcinomas showing a Ki67 proliferative index < 55% (b) show a
better survival than patients with Merkel cell carcinomas with a Ki67
index > 55% (c). Merkel cell carcinomas with Ki67 index > 55% were
observed more frequently in patients with disease, both died (DOD) and
alive (AWD) than in patients alive free of disease (AFD) or died for other
causes (DOC) (d)
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for the survival analysis. Regarding the first point, we are
the first to use the WHO recommendations by counting
the number of positive cells in at least 500 tumor cells in
hot spot areas on camera-captured printed images [4, 9].
As discussed above, the choice of 55% Ki67 cut-off was
based on the analogy with digestive NECs and on the
Youden index analysis. Our results on MCCs are in line
with those observed in digestive NECs that showed dif-
ferent survivals, when separated in two groups based on
Ki67 proliferative index (< 55% vs > 55%), [11].
However, although Ki67 proliferative index resulted sig-
nificantly associated with prognosis at univariate analysis,
together with tumor stage IV, MCPyV lack, and p63 ex-
pression [16–19], it was not an independent predictor at
the multivariate analysis, where survival resulted indepen-
dently influenced by p63 expression and tumor stage,
only.
The prognostic role of p63 expression is in line with pre-
vious findings [19], and it may be related to its function as
tumor suppressor as demonstrated in p63 knockout mice [43].
However, it is worth noting that different p63 isoforms exist
and may have distinct effects on oncogenesis. Since the anti-
p63 antibody used in this study does not distinguish among
different isoforms, we are not able to identify the p63 isoform
having the major pathogenetic role. Asioli et al. have demon-
strated that TAp63a and DNp63a were the most frequently
expressed isoforms (42%) in low-stageMCCs, suggesting that
an early anomalous regulation of their expression might de-
termine an aggressive phenotype [44].
In contrast to proliferation markers, a possible prognostic
role of factors influencing apoptosis has been poorly investi-
gated in MCCs. Indeed, although apoptotic cells were detect-
ed in MCCs using TUNEL, DNA ladder and immunohisto-
chemistry for Fas (Apo-1/CD95) [45], the prognostic role of
apoptotic index and of proteins and mediators involved in the
apoptotic machinery (Bcl-2, p53, surviving, and CXCR4) re-
mains to be elucidated [30].
In conclusion, this study, which integrates original findings
with literature data, is the first one analyzing the prognostic
role of Ki67 proliferative index in MCC using a standardized
methods of Ki67 evaluation. Nevertheless, althoughKi67 pro-
liferative index was associated with recurrent disease and
shorter patients’ survival at univariate analysis, it did not
prove to independently influence prognosis, which in our
Table 4 Review of the literature: prognostic role of Ki67 in Merkel cell carcinoma
Reference Year Number of cases Ki67 mean value Ki67 cut-off Correlation with recurrence and/or MTS Correlation with DSS
Parrado [27] 1998 25 40% nr Yes No
Carson [28] 1998 20 nr nr No^ No^
Jemec [15] 2000 13 nr nr nr No
Erickson [33] 2003 39 36.8% nr nr nr
Acebo [34] 2005 11 75% nr nr nr
Fernandez-Figueras [35] 2005 24 46.67% * Yes nr
Llombardt [29] 2005 20 nr 50% Yes No
Koljonen [36] 2006 24 47% 35% Yes nr
Tucci [30] 2006 12 nr # No No
Belhocine [37] 2006 11 50% nr nr nr
Pozo [38] 2007 27 46.97% nr nr nr
Asioli [19] 2007 47 50.6% 65% nr nr°
Kim [31] 2008 19 nr nr nr No
Sihto [16] 2011 91 nr nr nr nr
Lim [32] 2012 95 60% (median) 50% nr No
Henderson [25] 2014 21 nr nr nr No°°
Vujic [39] 2015 26 52% § Yes nr
Iwasaki [26] 2015 28 54.5% 60% nr No°°°
Lezoux-Kozal [40] 2015 15 46% nr nr nr
Orlova [41] 2018 32 nr nr nr nr
Kitamura [42] 2018 10 53% nr nr nr
Present series 84 51.3% 55% Yes No
MTS, metastases;DSS, disease-specific survival; nr, not reported; ^cases were considered positive when Ki67 > 10%; *not identified but metastases and
recurrence were observed when Ki67 > 54%; # not identified but worse prognosis were observed when Ki67 > 51.46%; °correlation with OS (p:0.001),
but not inmultivariate analysis; °°correlationwith OS (p:0.0597); § not identified but aggressive behaviorwas observed whenKi67 > 67%; °°°correlation
with OS (p:0.048)
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relatively large series mainly depended on high tumor stage
and p63 expression.
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